Chris Degnan Biography and Net Worth

CFO of Urogen Pharma

Chris Degnan joins UroGen with extensive experience and broad expertise in financial strategy, investor relations, SEC reporting, accounting, and compliance. He most recently served as Chief Financial Officer of Galera Therapeutics. Prior to Galera, Chris served as the Chief Financial Officer of Verrica Pharmaceuticals, a publicly traded biotechnology company focused on medical dermatology.

Earlier in his career, Mr. Degnan held senior positions at Endo International plc, including Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer. Before joining Endo, he spent more than 10 years at AstraZeneca plc, a global biopharmaceutical company, in roles with increasing responsibility.

Chris is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a Bachelor of Business Administration (BBA) in Accounting from the University of Notre Dame.

What is Chris Degnan's net worth?: The estimated net worth of Chris Degnan is at least $47.31 thousand as of October 8th, 2025. Degnan owns 2,280 shares of Urogen Pharma stock worth more than $47,310 as of February 24th. This net worth estimate does not reflect any other assets that Degnan may own. Learn More about Chris Degnan's net worth.
How do I contact Chris Degnan?: The corporate mailing address for Degnan and other Urogen Pharma executives is 400 Alexander Park, Princeton NJ, 08540. Urogen Pharma can also be reached via phone at (646) 768-9780 and via email at [email protected]. Learn More on Chris Degnan's contact information.
Has Chris Degnan been buying or selling shares of Urogen Pharma?: Chris Degnan has not been actively trading shares of Urogen Pharma during the last quarter. Most recently, Chris Degnan sold 2,203 shares of the business's stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a transaction totalling $37,120.55. Following the completion of the sale, the chief financial officer now directly owns 2,280 shares of the company's stock, valued at $38,418. Learn More on Chris Degnan's trading history.
Who are Urogen Pharma's active insiders?: Urogen Pharma's insider roster includes Elizabeth Barrett (CEO), Chris Degnan (CFO), Molly Henderson (CFO), Mark Schoenberg (Insider), and Jason Smith (General Counsel). Learn More on Urogen Pharma's active insiders.
Are insiders buying or selling shares of Urogen Pharma?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 57,279 shares worth more than $1,082,715.32. The most recent insider tranaction occured on February, 3rd when insider Mark Schoenberg sold 7,373 shares worth more than $145,174.37. Insiders at Urogen Pharma own 4.7% of the company. Learn More about insider trades at Urogen Pharma.
Information on this page was last updated on 2/3/2026.

Chris Degnan Insider Trading History at Urogen Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/8/2025	Sell	2,203	$16.85	$37,120.55	2,280

Chris Degnan Buying and Selling Activity at Urogen Pharma

Urogen Pharma Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Today's Range

Now: $20.75

$20.61

$21.39

50 Day Range

MA: $21.35

$18.74

$23.75

2 Week Range

Now: $20.75

$3.42

$30.00

Volume

390,219 shs

Average Volume

702,776 shs

Market Capitalization

$971.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32